Low CH50, normal AH50, or vice versa— diagnostic developers use this straightforward functional testing pair to rapidly localize a complement deficiency to the classical or alternative pathway, then deploy specific immunoassay raw materials to quantify the exact protein culprits. By comparing the lytic activity of the classical (CH50) and alternative (AH50) pathways, a lab can immediately rule out entire arms of the cascade, eliminating guesswork and directing precious resources toward the handful of components most likely to be absent or consumed. This integrated workflow saves time and cost while delivering confident, molecular-level diagnoses.
The diagnostic logic is simple: a low CH50 with normal AH50 points to deficiencies in the classical pathway‑specific proteins C1, C4, or C2; a low AH50 with normal CH50 indicates alternative pathway factor defects (Factor B, Factor D, Properdin); and low values in both tests signal a terminal pathway bottleneck (C3, C5–C9) or systemic consumption. To precisely identify the missing component, developers build reflex panels using high‑affinity antibodies, purified antigens, and standardized calibrators targeting those exact proteins.
How Functional Screening Narrows the Search: The CH50/AH50 Pattern
Pairing CH50 and AH50 functional assays is the cornerstone of complement deficiency investigation because each test selectively activates one pathway, making the result pattern diagnostic on its own.
Interpreting the Classical Pathway Signal
A CH50 assay measures the serum dilution needed to lyse 50% of antibody‑sensitized sheep erythrocytes, probing the entire classical cascade from C1 to C9. If the CH50 reading is abnormally low while the AH50 remains in the normal range, the defect must lie in a component that the classical pathway requires but the alternative pathway does not—C1q, C1r, C1s, C4, or C2. These proteins form the C3 convertase (C4b2a) exclusively via the classical route, so their deficiency spares the alternative pathway.
Recognizing Alternative Pathway-Only Deficits
The AH50 test uses unsensitized rabbit erythrocytes and a calcium‑chelating buffer (EGTA‑Mg²⁺) to block classical activation, revealing alternative pathway lytic function. When AH50 is low and CH50 is normal, the problem resides in Factor B, Factor D, or Properdin—the unique building blocks of the alternative pathway C3 convertase (C3bBb). This pattern immediately excludes C1, C4, and C2, condensing the follow‑up target list to just three factors.
Catching Terminal Pathway and Consumption Problems
If both CH50 and AH50 are depressed, the defect is either in a shared component downstream of both C3 convertases or due to massive complement consumption. The most clinically urgent possibility is a primary C3 deficiency, which cripples all activation routes. Other terminal components (C5 through C9) or even a consumed state from an autoimmune flare yield the same dual‑low pattern, demanding broader quantification.
The Reflex Testing Foundation
With a functional pattern in hand, diagnostic developers design a reflex panel that automatically triggers the right quantitative immunoassays. For a classical pathway hit, the panel tests C1q, C2, and C4. For an alternative pathway signal, it targets Factor B and Factor D. When both pathways fail, the reflex panel expands to include C3, C5‑C9, and possibly regulatory proteins such as Factor H and Factor I to distinguish primary deficiency from consumption. This intelligent cascade spares the laboratory from running a full complement of single‑analyte tests on every sample.
IVD Raw Materials That Make Follow‑Up Testing Possible
Transitioning from functional screening to precise protein quantification demands a suite of high‑quality raw materials, each engineered for robust and reproducible performance.
High‑Affinity Antibodies for Individual Component Measurement
Quantifying C1q, C2, C4, Factor B, or C3 requires monoclonal or high‑affinity polyclonal antibodies raised against these specific proteins. These antibodies form the detection backbone in turbidimetric, nephelometric, and ELISA platforms. Developers select antibody pairs that recognize distinct epitopes, ensuring minimal cross‑reactivity with other complement proteins or abundant serum proteins like albumin, which would otherwise distort low‑concentration measurements.
Purified Complement Proteins and Reference Standards
Accurate quantification is impossible without high‑purity native or recombinant complement components to build standard curves and quality controls. Purified C3, C4, Factor H, and Factors B/D serve as calibrators, verifying assay linearity and lower limits of detection. Batch‑to‑batch consistency of these proteins is paramount; even minor degradation can skew whole‑assay performance and lead to misdiagnosis.
Specialty Reagents for Functional Screening Kits
While follow‑up testing leans on immunoassays, the integrative CH50/AH50 screening step itself demands specialized materials. Sheep erythrocytes sensitized with rabbit anti‑sheep hemolysin (for CH50) and unsensitized rabbit erythrocytes (for AH50) must be stabilized and supplied with detailed lytic performance data. The AH50 buffer must contain EGTA and Mg²⁺ ions to chelate calcium, preventing any classical pathway interference, and these buffers require lot‑tested reference sera to verify their selectivity.
Complement‑Depleted Sera as Negative Controls
Every quantitative assay needs a true blank. Complement‑depleted sera—i.e., sera documented to lack the target analyte— provide the zero standard and serve as a diluent for constructing calibration curves. For example, Factor B‑depleted serum is essential for an alternative pathway reflex assay, ensuring that signal background is truly derived from patient fluid and not reagent contamination.
Navigating the Trade‑Offs in Assay Development
Even a well‑reasoned workflow carries inherent challenges that diagnostic developers must mitigate.
Labile Proteins Demand Cold‑Chain Discipline
Many complement proteins, especially C2 and Factor B, are heat‑labile and prone to activation or degradation during storage. Developers must source lyophilized or liquid reagents formulated with stabilizers, and rigorously validate shipping and on‑bench stability to prevent false‑low readings caused by reagent decay rather than patient deficiency.
Sensitivity vs. Specificity in Reflex Immunoassays
A reflex panel targeting low‑abundance proteins like C2 must balance analytical sensitivity (the ability to detect mild deficiencies) with diagnostic specificity (avoiding false positives from cross‑reactive antibodies). Using highly validated antibody pairs and blocking agents reduces non‑specific binding, but this often increases raw material cost and development time—a trade‑off that must be weighed against intended clinical use.
The Standardization Challenge
There is no universal reference method for many complement component measurements. Lot‑to‑lot variability in calibrators and reference sera can cause drift between laboratories. Developers mitigate this by aligning their products with international standards (when available) and providing a value‑assignment protocol with every kit, but maintaining inter‑laboratory concordance remains an ongoing effort.
Making the Right Choice for Your Diagnostic Development Goal
Whether you are designing a screening system or building a full complement deficiency panel, your decision tree should be driven by the clinical question you need to answer.
- If your primary focus is building an entry‑discriminating screening kit: Ensure your CH50 and AH50 reagents—erythrocytes, activator buffers, and reference sera—are optimized for clear pattern recognition, with robust negative controls for both pathways.
- If your primary focus is developing reflex quantitative immunoassays: Prioritize high‑affinity antibody pairs against C1q, C2, C4, Factor B, and C3, backed by purified calibrants and component‑depleted sera to guarantee sensitive, specific single‑analyte output.
- If your primary focus is manufacturing stable IVD raw materials for complement testing: Invest in formulation studies that lock in protein stability and provide end‑users with clear storage, handling, and lot‑to‑lot comparability data to keep the entire diagnostic cascade reliable.
A well‑designed complement deficiency workflow turns a simple pair of functional lytic tests into a precise molecular diagnosis, but it depends entirely on the quality of the antibodies, proteins, and reference controls you build into each step.
Summary Table:
| CH50 / AH50 Pattern | Indicated Pathway Defect | Target Complement Proteins | Essential IVD Raw Materials Needed |
|---|---|---|---|
| Low CH50, Normal AH50 | Classical Pathway | C1q, C1r, C1s, C4, C2 | High-affinity C1q/C2/C4 antibodies, purified proteins, C-depleted sera |
| Normal CH50, Low AH50 | Alternative Pathway | Factor B, Factor D, Properdin | Factor B/D antibodies, purified Factors B/D, Factor B-depleted serum |
| Low CH50, Low AH50 | Terminal Pathway or Consumption | C3, C5–C9, Factor H, Factor I | Antibodies & calibrators for C3/C5–C9, sensitized/unsensitized erythrocytes |
Accelerate Your Complement Diagnostic Development with CamelBio
Whether you are designing lytic screening assays or building high-precision reflex immunoassay panels, CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—covering every stage from concept to clinic.
From high-affinity antibodies and purified complement proteins to specialty buffers and component-depleted sera, we deliver the quality and lot-to-lot reliability your assays demand.
Contact CamelBio today to request sample materials or consult with our technical team.